4/A//SEC Filing
Hively Brad 4/A
Accession 0000935836-25-000296
CIK 0001799191other
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 7:20 PM ET
Size
9.4 KB
Accession
0000935836-25-000296
Insider Transaction Report
Form 4/AAmended
Hively Brad
Director
Transactions
- Purchase
Common Stock
2025-03-26$1.04/sh+45,280$47,168→ 712,033 total - Purchase
Common Warrant
2025-03-26$0.13/sh+22,640$2,830→ 22,640 totalExercise: $1.20From: 2025-03-26Exp: 2030-03-26→ Common Stock (22,640 underlying)
Footnotes (5)
- [F1]This amendment is filed to correct the number of shares of Common Stock and number of Common Warrants acquired by the reporting person in the transaction reported on the original Form 4 filed on March 28, 2025. As a result of this correction, the amount of securities beneficially owned following the reported transaction specified in Table I, Column 5 and Table II, Column 9 have also been corrected.
- [F2]Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
- [F3]The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- [F4]Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
- [F5]The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act.
Documents
Issuer
Oncology Institute, Inc.
CIK 0001799191
Entity typeother
Related Parties
1- filerCIK 0001891124
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 7:20 PM ET
- Size
- 9.4 KB